Monday, November 28, 2022

Jonah's new word #Exhausted #CUREmps #GivingTuesday

Jonah’s new word.

 

I said I wasn’t going to write for a while because I’d be too busy. However, I’m still waiting for Columbia Presbyterian’s Internal Review Board (IRB) to come back with the green light so we can start enrolling patients for our IIID observational study! I’m growing more and more impatient as the days pass.  Thought I’d take a moment to hit you up for some cash. The 29th is GivingTuesday and the Sanfilippo community is fundraising to help support our programs. https://www.facebook.com/donate/650264436504687/650264453171352/  Here is my fundraiser, if you don’t use Facebook, I applaud you and offer you an alternative way to donate. You can write a check to the Cure Sanfilippo Foundation, write Jonah in the memo line and post to: Cure Sanfilippo Foundation PO Box 6901 Columbia SC 29260

 

I’m constantly looking for evidence that Jonah is still learning. The other day Jonah and I were playing with his bat cave houses and figures, DC inspired doll houses and action figures. Jeremy and I use this activity to reinforce expressive and receptive communication. The DC characters knock on the bat cave door and greet whoever answers. We ask each other questions about what they’re doing today and encourage Jonah’s figure to ask us questions back. Jonah asked me where Wonder Woman and Harley Quinn were, I told him that they were having pizza at the pizzeria. I asked him how Superman was doing, Jonah responded, “Oh he’s exhausted.”

 

On one hand I was very proud of Jonah for using a new word on the other I felt super guilty for telling him how exhausted I am all the time. The next day I booked us a trip to the Adirondacks for the long Thanksgiving weekend. It was fabulous, I had the most glorious spa day, I hardly thought about work and completely ignored how much money we spent on treating me. Jeremy and I forced Jonah to go on a hike through the snow and rain and rewarded him with movies and peanut butter Nutella sandwiches. We found him a playground too! I didn’t spend two days cooking; all in all, we had a delightful time. Hope everyone else had a lovely day too.


I worry about Jonah more than usual; I see physical changes, he’s 14, it’s too be expected. I ask myself: has he always tripped in cracks or is this new? How long has he been coughing for? He doesn’t seem to hear half of what I’m saying. Jonah has new orthotics, he’s taken too them well. They slip into his shoes, so no one can see them, they help brace him, so his ankles don’t turn as easily. Jonah’s ankle turns on him frequently when he walks along the seam of the sidewalk or hits a dip or crack along the path. I cringe every time he does it. He yells at me I’m okay I’m okay mom. Writing about it makes me cry. He shouldn’t be tripping in a tiny crack. 

 

He coughs excessively after he eats, which is a sign of a swallowing issue. We finally got him an appointment to see a speech and eating expert to evaluate him. We’re going in tomorrow.  I’m hypersensitive of the swallowing issues as our kids predominantly die of aspiration pneumonia. Jonah doesn’t drool which is a good sign. We must get through the evaluation before they schedule the swallow study. I'm super anxious to find out if there is an issue or not.


His hearing has gotten me really worried too. Jonah wears his hearing aides all day at school. I let him take them off before he gets on the bus to come home. At first it was a precaution as to not loose them. If I’m being honest with myself, it’s more of an excuse to not have to fight with him at home to wear them. He constantly asks us what. I say his name when he’s not looking, and he doesn’t respond. He doesn’t hear the door open and shut when I come home. My next goal is to get him a sedated hearing test so we can find out the true extent of his hearing loss. If he can’t hear his ability to learn and comprehend will suffer. I’m wondering if a cochlear implant might be an option for him. 


I wanted to add some of these assessments to our IIID observational study, ALL-127. I had to let go of the sedated hearing and eye exam because it was too expensive. My team shot me down on the BARIUM swallow test sighting patient fatigue from all the assessments. Our kids can’t perform the typical hearing assessments, they don’t have the cognitive capabilities to answer the questions. Vision loss is another issue that we can’t assess as our kids can’t sit still long enough to take an image of the retina. I’m looking at the swallowing and gait issues from a neurological standpoint. Sanfilippo syndrome is primarily a syndrome of the Central Nervous System (CNS). The FDA wants to see neurological improvements after treatment. This is extraordinarily hard to deliver on our patient population. It would be easier to do if the syndrome wasn’t so rare. For instance, if we had 20 kids of the same age, speaking the same language and progressing at the same rate we’d have a cohort that was easier to draw conclusions from. 

 

The current way that cognitive function and expressive receptive language is assessed does not work for our, in part non-verbal, multiple languages and severely cognitively impaired population. The assessments used during most trials are not designed for such a diverse group of individuals. Furthermore, the assessments don’t come translated in all the different languages. To have an assessment translated you must first license the assessment, then pay to have someone translate it, then pay again to have the authors of the assessments approve the translations then pay for the certification of the translations to present to the IRB and FDA. Depending on the length of the test, this can easily end up costing $50,000 per language. For our trials we’re using the Leiter-3 which is designed for a non-verbal patient population, so I don’t have to pay to translate it to ten different languages. The drawback is that it won’t capture the receptive/expressive skills and it takes more expertise to administer.


To make up for the lack of standardized assessments available to use on our trials, my team created a protocol of activities of daily living (ADLs) that are to be filmed on a smart phone recording application. The app is called RARE (IIID) and C-RARE (IIIC) Recording Application for Real-world Evidence. The RARE app is hosted on Atom-5 and managed by the company, Aparito. The participants will be consented through our IRB approved protocol by the clinicians conducting the study. When the participants are on boarded, they will be given a code to download the app and a user manual explaining the study and instructions for recording the video tasks. The ADL tasks to be recorded are of the child performing the tasks in real-life under natural circumstances. The RARE app tasks are modeled after the domains of the typically used standardized assessments which are administer to the patient by the physician in a hospital.   

 

This project took a year to design, it is extensive and as clinical as we could make it without disturbing the child’s natural routine. We will capture the expressive/receptive language that the Leiter-3 doesn’t capture during the video tasks. All this will need to be scored by an independent panel of therapists and raters. I already feel like I'll be doing this project for the rest of my life. It's going to be epic!


We’re trying to capture and score the incremental changes of this slowly progressing CNS disorder. The video’s will be done over the same time-points of the child’s clinical visits at the hospital and every 6mo in between the site visits. The study will pick up again after the participant receives drug intervention. The ALL-127 Sanfilippo type D study design has been funded by our NIH/NINDS SBIR grant. It wasn’t a stretch to adapt it for IIIC. We’re now working on designing questionnaires to add to the C-RARE app. The C-RARE app questionnaires, instructions, and caregiver manual will need to be translated to numerous languages and the management of the app, scoring, and data collected still needs funding. However, the cost of creating our study from scratch still doesn’t even begin to compare to having to license and translate the assessments that are typically used for Sanfilippo trials. Fingers crossed it all works!

 

The mom that inspired me to create Phoenix Nest, Karen Aiach the CEO of Lysogene has released the most comprehensive results of her San A gene therapy trial to date. You can listen and watch the presentation here https://channel.royalcast.com/lysogene/#!/lysogene/20221123_1

 

It is very reassuring that the treatment has significantly impacted the progression of the syndrome in the little kids, under 30mo. It showed no difference on the primary endpoints for the older kids which is hard for our patient community to hear and accept (including me, Jonah is 14.) The primary endpoints included improvement of the scores of the cognitive assessments BSID-II and the KABS.  FYI, once a sponsor decides on a primary endpoint for their phase II/III interventional trial, they can't go back and change it. Once you choose it you're stuck with it and you must show that you improved the endpoint for drug approval. There is a lot of discussion around choosing the 'right' endpoint, but not enough discussion on how to measure that 'right' endpoint. 


I'm banking on findings provided by our RARE app and our different choices of clinical assessments to give us a deeper and clearer picture of the incremental improvements of the treated older patients. I believe we will also settle on a better 'right' endpoint and we will have better tools to measure our primary endpoint.  With any luck my grammar might improve one day too.


No matter what when our trials are completed and we have concrete evidence that the drug indeed works on the brains of pre-symptomatic children we will have a 'cure' for the next generation of kids. That is something to celebrate and I think Jonah would agree, he loves his friends deeply and hates to see anyone in distress. We have the sweetest kid ever, see for yourself. 


As always thanks so much for your continued support and Happy Holidays!




 


 To Donate go here:

 https://www.facebook.com/donate/650264436504687/

Sunday, September 11, 2022

Cyclone

 

Coney Islands infamous Cyclone roller-coaster doesn’t hold a candle to my life. My life is so scary... How scary is it you ask?  It's so scary that I recently threw-up in my Dutch Bros cup.

 

Jonah attends school year-round. He has a small break at the end of summer before school starts up again.  I was torn between going to Oregon so he could have some family time or staying home so I could work. Jonah’s break coincides with one of the NIH/NINDS grant funding rounds. I had PTSD just thinking about being in Oregon last summer when our current grant was funded.

 

These grants are our community’s lifeline, I need to be able to drop everything to respond to an NIH/NINDS grant inquiry. The federal government takes them just as seriously. When you’re notified that your grant has been ‘recommended’ for funding you’re requested to submit numerous supporting documents. The process is called Just in Time (JIT), half of the supporting docs are regarding company financials. It’s basically like taking out a mortgage and closing on a house. The other half of the JIT articles relate to your grant’s specific aims.  You’re given a deadline to get everything in, if you miss it, you miss the funding round, hence the acronym JIT.  Last year’s grant included human participants, which involved getting certifications completed for JIT. It was intense and being 3 hours behind the east coast makes everything just a little bit harder. I knew if I went home this September that I could be in double trouble, but I went anyways.

 

Double trouble, we have potential funding coming in and we’re resubmitting the same grant just in case we don’t get awarded this time. Back story last spring, we won a grant, but funding was ‘deferred’. We received a great score, what they call an awardable score, but due to budget cuts only the perfect and near perfect scores got funded. Deferment meant that if another awardee did not make a milestone, then PN could get their funds. By September 5th we’d find out if somebody missed their milestones so that our ‘deferred’ grant could be awarded. September 5th was also the deadline for re-submission. Our program director told us to be prepared for both case scenarios.

 

PN’s Scientific Director, Sri does the grant writing, my job is to create the budget and gather the letters of support (LOS). It’s me that presses the submit button, so I need to be next to my computer and ready to trouble shoot error messages. I’ll tell you about error messages another day. I booked our tickets to Oregon and spent the next three days pulling together all the JIT articles that I knew they’d ask for and at the same time asked our collaborators for updated LOS. An outdated LOS or quote can give you bad marks on a submission and ultimately cost you the grant. Meanwhile Sri worked on updating quotes and adding in the new data. The second day into our trip to OR we received the letter acknowledging that our deferred grant had now been recommended for funding! JIT requests started coming in. At this point you’re still being warned not to get too excited, it’s not a done deal until the notice of award (NOA) is sent out.

 

One of the JIT requests questioned our use of a foreign research organization to manufacture our vector. The NINDS gave us 3 options the first was to find a US based manufacturer.  This is not something that can be done in a few days. The thought of even trying to make this happen was staggering. The wait times for vector manufacturing can be over a year, the work involved is extraordinarily detailed, it costs millions of dollars. Manufacturers need to have the blueprints to our construct; they must have internal meetings to discuss if their facilities can even do the work. The second option was to pay for the vector out of our own pocket, moot point. The third option was to submit a justification as to why we had to use the foreign component. I thought we had sufficiently justified the need for the foreign manufacturer in the body of our grant. If the reviewers didn’t think that justification was good enough, then what else could we say to them now?!

 

I talked to Sri first thing in the morning, he assured me that we had good justification, he reiterated our stance in a letter to NINDS and we submitted to JIT. The next question from NINDS was for the credentials of the foreign manufacturer, which is Viralgen by the way, they’re located in Spain.  Our grant program director said that funds going to Spain had to be approved by the State Department. Who says that? Well, who says that to little ole’ me anyways? I must get it approved by the State Department. Ha! She also informed us that approval could take a while. I thought to myself, no way we’re getting approval in time; good thing we re-submitted.

 

This was now the fourth time we submitted our gene therapy grant (JLK-247) for San C. The second time we submitted the grant it was kicked back due to ‘overstuffing’.  Overstuffing... we had included FDA comments that the grant submission portal ‘gatekeeper’ (for the lack of a better title) said to be against grant rules. Our justification for doing this was because the first time we submitted the grant and didn't win, the reviewers commented that they’d like to see if the study design had FDA buy-in (I’m paraphrasing). We went to the FDA, received the nod, and included their comments regarding our study design to the grant as a letter of support and resubmitted. The gatekeeper did not like that approach and accused us of trying to get around the grant page limit by adding in FDA comments as a LOS. For the record we also added the comments in the body of the grant. We included the official comments as a LOS because we thought it was a nice touch and our program director agreed.

 

Sri and I fought for the grant to be permitted through and asked to let us go with a warning. She could have redacted the portion of the FDA comments that she felt were unfair (I'm pretty sure she actually used the word egregious) to the other applicants. It was a heated conversation. The gatekeeper demanded that I put in writing my justification as to why I was so special that I got to cheat (I’m not paraphrasing). At this point I was foaming at the mouth.  I have a consultant that advises us on grant submissions, he highly recommended that I drop it, that I was not going to win this argument. I let it go and we resubmitted four months later at the following submission date; this is the grant that got deferred.

 

Not that we have come full circle, did we win the grant or not?  I don’t know, I do know that the State Department approved our justification to working with Viralgen!  I’m thrilled but trying to temper my expectations. I think we’re just waiting on the OLAW (Animal Welfare Assurance) confirmation now; we sent it in on Thursday but no response if it was enough. Radio silence.

 

There have been a handful of diagnosed San C patients this year. It’s always how long how long how long. I respond I don’t know, it’s not up to me. That doesn’t stop them from asking. I don’t blame them; I know exactly how they feel. What brings me to tears is the overwhelming feeling of helplessness, drug development does not come with a GPS! I'm trying to go as fast as I can families.

 

The grant funds will cover the study that analyzes the tissue from the mouse dosage study using our new vector (JLK-247) this study was supported in part by the Cure Sanfilippo Foundation. Among other things we will be looking at the biodistribution of JLK-247. If it and everything else is good, then we can go to the FDA and ask if we can go to trial. If they’re not convinced, we’ll have to do another animal study.

 

It has been an extraordinarily busy year. The grant that was awarded this time last year is funding for the Natural History Study (NHS) protocol design and implementation of Sanfilippo syndrome type D, the program name is ALL-127. I’ll spare you the gory details of securing that funding and skip to the exciting part. Writing a clinical protocol 101: Patient input matters more than most sponsors imagine. The FDA talks about how important patient engagement is for selecting endpoints and trial design every chance they get. I’m not getting the sense that sponsors have really understood or taken to heart that message. They can’t just send out a survey asking families what the biggest burdens are. That isn’t good enough.

 

Patients need a seat at the table, not just metaphorically but literally. We need to have a say in how the symptoms are measured. Some symptoms (endpoints) are easy to measure- straight forward. In the case of Sanfilippo there is not one endpoint that is straight forward or easy to measure. Which is mind-blowing because the syndrome affects every system of the body. It hits the central nervous system (CNS) the hardest, a hit to the CNS radiates out to the all the other bodily systems.  Affecting the way our kids: walk, talk, eat, think, sleep pee/poop, process sensory input and behave. The children’s other organs are affected as well but the impacts are subtle and don’t cause immanent death. Unless their lungs fill with fluid from pneumonia, which doesn't make for a good endpoint either.

 

For the Sanfilippo community communication and mobility are two of the top-ranking symptoms. Improvement in communication gets lost in translation to sponsors. We can’t just say improvement in communication to a sponsor. The sponsors think speech. A parent of a Sanfilippo child sets the communication bar much lower. We want our kids to be able to communicate non-verbally, it can be as simple as a smile. A smile from our kids means everything to us. Think about it, what if your loved one stopped smiling? Will the FDA approve a million-dollar drug for smiles? A million-dollar smile, totally worth it 😊.  

 

In the case of Sanfilippo, sponsors have leaned on cognitive tests for measurement of treatment improvement, think of the SAT. These types of assessments are guarded by the authors and license holders. To see them you must have your clinical team lined up and prove your intent of conducting a clinical trial. When we first wrote the grant, we had to include a synopsis of our intended clinical protocol for ALL-127. We chose assessments that were used in the other clinical trials for San A and B. At this point I had still not gained access to the cognitive assessments. It wasn’t until after the grant was awarded and our site and clinicians had been secured that I was permitted to see the assessments. By then we had finalized our protocol and sent it in for IRB approval, this was no small feat. 

 

After reviewing the assessments well if you can’t guess by now… I was nauseous and plagued with doubts.  The assessments in my opinion were not appropriate for the Sanfilippo patient population. At the same time, our FDA comments came back, they had reviewed our protocol and had numerous suggestions regarding out choice of cognitive assessments. The final straw was the results from the failed and divested San A and B drug trials that were finally being published. The data suggested further that the chosen cognitive assessments were not appropriate to measure their endpoints. Our ALL-127 protocol had literally just received IRB approval; we could start recruiting patients soon. We were faced with a major decision- continue with the status quo or start over. We started over. Now we were faced with missing a milestone and not  having funds released in time to continue study startup. It’s a non-stop roller-coaster ride. I can’t say I never catch a break; the break was getting the chance albeit a last-minute chance to right a wrong. We were left with now trying to find the assessments that would work.

 

As mentioned, you can’t go to a library or store and browse through all the assessments available to license and use in trials. We must work with the companies that own them. They have specialists that help you zero in on topics of interest, I combed through endless assessments. Nothing was right. I called on Jonah’s therapists. Who better to point me in the right direction then the teachers on the front lines administering these tests to kids like Jonah. His therapists gave me a list of tests, which I then requested to view from the owners. My guy chuckled when he pulled them for me. He said he wasn’t even aware that they owned the assessments, they were so old. On that note… I finally had something we could work with. The ALL-127 protocol is now finished and back with the hospitals Internal Review Board (IRB). We anticipate approval to be coming in a few weeks. Our site initiation visit is set for October 14th. Our goal for first patient in is end of October early November. We will make our first milestone and be able to bring the rest of the participants in for screening and baseline after the new year. After that the participants will come in for two more annual visits.  Meanwhile the ERT mouse toxicology studies for ALL-027 will wrap up and we will head back to the FDA. If all goes smoothly the ALL-127 patients will proceed into the interventional trial. Truth be told I’d like to extend the study for at least a third year, sadly we don’t have the budget for it.

 

The study is extraordinarily expensive. Our hope is that once we start accumulating the natural history data that we will garner more pharma interest and find a financial partner. I have a feeling that once the study is published on clinicaltrials.gov that we will have more patients wanting to participate. It would be amazing if we could include all the San D kids that wanted to come. The participants are coming from around the world, over half of them don’t speak English. We must translate all the consents and other patient facing documents to their native languages and bring in translators to help them throughout the study. ALL-127 doesn’t just include cognitive assessments, there are numerous physical and clinical tests as well.  Labs, sedation for x-rays and MRI. It’s no walk in the park for the children or their parents. Their commitment to the study and desire to help bring forth a treatment is nothing less than heroic. 

 

The ALL-127 protocol is going the extra mile by including a video collection of daily living activities (ADLs) shot at home by the children’s caregivers.  There will be a retrospective portion as well, all the patients’ medical records will be reviewed for the onset of disease symptoms. All the data gets imputed by the site coordinator into a controlled data base. It took our team (Labcorp) almost a year just to design the database, in their defense I did keep making changes to the protocol.

  

I’m extremely proud of the video portion of the study, we’re working with Aparito, a company that has licensed HIPPA and GDPR compliant software program to manage patient data. With the help of our patient community our team came up with several activities that we hope will capture the participants real-time real-world experiences. Caregivers will video children performing daily activities in a natural setting, within standardized parameters for video capture which will hopefully cause minimal disruption in their daily routines. The video activities compliment the assessments performed in the clinic. The idea is to visualize, describe and score the children’s behavior, movement, communication abilities, and yes smiles that are hard or even impossible to capture in the clinic. Remember our young kids are always on the move, they can’t sit still and tend to run away. Our advanced kids smile if we're lucky, they're cared for 247. I'm hoping that our video tasks will capture a few smiles and any incremental improvements seen by families after intervention.

 

These videos are taken on a smart phone using an app, the families are given a secure QR code where they download the app, which has been designed and translated to walk them through all the activities and questionnaires. The videos will be taken within 14 days of the clinical visits and at 6mo time points in between the clinic visits. We named the app RARE Recording Application for Real-world Evidence. The San C version is called C-RARE, get it? Sri came up with the acronyms.

 

When supporters donate to medical research, the primary thought is the cost and time of drug discovery in the lab. This is the tangible portion that can be visualized. It’s the behind the scenes and back-end work that you don’t see that takes just as much time and funding resources as the laboratory research. The contracts, study design and quality checks are sucking up all my time. Everything that goes into drug discovery must be meticulously collected, scored, and stored for FDA review.

 

In between reviews I have been working on new quality of life and clinical outcome questionnaires tailored to absorb as much as we can out of the Sanfilippo patient experience. These types of questionnaires are called Clinical Outcome Assessments (COAs) the cognitive assessments also fall under the COAs. Over the past ten years I have been told on numerous occasions that it is too hard to design and validate syndrome specific COAs. That I’d be wasting time to even try because the FDA wanted the ‘gold standard’ validated assessments that have been used in thousands of trials. It later occurred to me that the advice was coming from people that didn’t have a full understanding of the progression or phenotype of Sanfilippo syndrome or that the FDA had extremely little experience with Sanfilippo. It’s only been 10 years since the very first San A trial started. The FDA is just now wrapping their brains around the data coming from these trials. They have had a steep learning curve. 

 

A few months ago, the FDA came out with a new guidance that states if there is not an assessment available that is sensitive enough to measure your target endpoint, then make a new assessment, they go on to walk you through how to do it. I had already started to create a COA to measure behavior when this guidance came out. The FDA guidance was the push I needed to create a series of Sanfilippo specific COAs. The Sanfilippo families have been guiding us on the development of these COAs, patiently walking through every question and giving their feedback and suggestions for improvement. It has been an extremely rewarding experience for all of us.  My team engsged a couple of expert clinical assessment designers to help us with the scoring and wording of the questionnaires. When finished we’re going to pilot the COAs on the C-RARE app. We didn't finish the new COAs in time for the ALL-127 launch. They will however be done by the ALL-027 intervention trial.

 

The JLK-347 clinical protocol is being scrubbed by Labcorp’s quality control team right now!  Labcorp is the CRO managing our studies and storing the data.  We’re planning 2 sites, one in France and the second in the US. While the NHS for San C gets underway, we will finish up the tox and biodistribution animal studies (contingent on the grant coming in). The plan is for JLK-347 participants to transition straight into the interventional trial, JLK-247 and become their own controls. 

 

PN has been working on a third program that is suitable for all Sanfilippo subtypes, AVP6. It’s a peptide administered nasally which increases synaptic function. It’s an option that will pair nicely with gene therapy and ERT interventions.

 

I have taken the time to give you all an extra-long blog as I plan on being too busy to write again for another year! Tomorrow we will win the JLK-247 grant and begin our next chapter. Watch for the press release on Linkedin.Fingers crossed.

 

Quick Jonah update, he is doing great! He's still smiling and still learning. He just started his freshman year! Jeremy and I are so incredibly proud of him. This kid is fighting his fate like, Batman, his favorite superhero and he doesn't even know it.


 

I gave a few talks this year:

ADVANCE Sanfilippo syndrome workshop Cure Sanfilippo Foundation   

https://www.youtube.com/watch?v=UbtxDl20TyQ&t=3s                                      

My talk is on the ALL-127 program and RARE app. It starts at 1:30ish.  Phoenix Nest had three other talks. Srikanth Singamsetty discusses JLK-247, Tsui-Fen Chou speaks about ALL-127 and Alexey Pshezhetsky gave a talk on AVP6. The AVP6 talk and it's data were not published for wide distribution. You will have to wait until we publish.

NINDS Nonprofit Forum 2022

https://videocast.nih.gov/watch=45549

My talk starts at 2:17ish on day 1. Please watch the talk right after mine with Emily Caporello, NINDS and put a face with my "program director".


Decision Vision Podcast

https://businessradiox.com/podcast/north-fulton-studio/decision-vision-apply-for-grants-jonahs-just-begun-sanfilippo/

I spoke on my experience with applying for NINDS SBIR/STTR grants

 

RDLA- Rare Disease Week 2022- Policy Deep Dive: Speeding Therapy Access Today (STAT)act

https://www.youtube.com/watch?v=btB0cCzWoM8 

Spoke to how federal funding helps the ultra-rare disease community! My talk starts at 1ish


Check out the new FDA fit-for-purpose clinical outcome assessment guidance.

https://www.fda.gov/media/159500/download



Monday, June 13, 2022

Happy Birthday to me

 

Happy Birthday to me.

Phoenix Nest headquarters (HQ) are located at Industry City (IC) in what used to be known as Bush Terminal.  A massive manufacturing and distribution plant built in the 1890’s, 16 buildings on 35 acers right off the Gowanus Canal. In the 60’s there was a mass exiting of the manufacturers at Bush Terminal and the buildings fell into disrepair. Today they have been built back up but are still in keeping with their industrial roots. My loft space is rustic; beatdown in a good way, the best feature it’s windows. It is the ideal location for a houseplant garden. PN HQ is a silver lining on the horrors of my job. I feel like I can breathe here. Jonah loves it too, there is a great Pizza joint downstairs and a foosball table in the arcade room, but mostly he likes it for the tv.  My favorite addition to IC is the Little Pot of Soil, a plant shop down by the pizza joint. I think they put it in just for me. IC is my happy place; it must be as I pretty much live here. I received a B.day check in the mail from my mom yesterday and spent the whole thing on plants and pots for PN HQ. It was a good birthday.

 


I realize that I haven’t shared anything since Elouan passed away. I want to be able to get online and say we’re all done, Sanfilippo has been cured and we can all go home now. The reality is that research and drug development take a long time. There are hundreds of opportunities for setbacks. We try to control everything we can, but research is unknown, that’s why it’s called research.

 

For example, our IIID Enzyme Replacement Therapy (ERT), All-027 program enzyme didn’t like its food or temperature and wouldn’t grow. It took us a year to figure out the right food and temperature combination. That stretched our grant out an extra year. We ended up doubling the length of our IIIC mouse dosage study for JLK-247. Our mice were supposed to come down at 32 weeks, but we decided that the behavioral dated would be better supported with additional survival data. We extended our study to 70 weeks and just now took the rest of the mice down. Which again sucked up more funds. If only the money just flowed… Our third therapeutic study, AVP-6 hasn’t run into any major challenges.  We’ve gotten lucky thus far. Knock on wood.  

 

Last summer we won a NIH grant to support the observational study for ALL-127 (Natural History Study for IIID). The startup of this clinical trial has been exactly what I expected it to be, terrifying! I’ll go ahead and break it down for you. We have our main contract research organization CRO, Labcorp/Covance, these guys build the electronic Case Report Forms (eCRF) for us and store the data that comes out of the observational trial. They write the informed consent forms (ICF) and provide medical writers for our clinical protocol. They make sure we don’t miss anything and keep every letter in compliance with our regulator’s guidelines. The paper trail involved is astronomical. At the end of the study, they will do all the statistical analysis. All this costs just as much as the clinical trial itself. Secondly, we have the hospital site, they see the patients and perform all the assessments listed on the clinical protocol that we designed.  After each patient they input all the medical report results into the eCRF. We have two additional CROs that have helped us design a real-world real-time app. We call it the ‘RARE’ app. For the app we chose several daily activities for the caregivers to video record, this too, is a methodical research project. On top of that we will have a retrospective study where the patients will provide our study site with their medical records. The primary investigator (PI) will comb through the records and pull out our needs. The patients will come to NYC for a total of 3 visits over the course of three days for two years. The kids will go through a battery of clinical and cognitive assessments. First Patient In (FPI) was supposed to be in March we’re looking at September/October now. A few things happened, first we decided to move sites from Yale to Columbia. Secondly, was the change of cognitive assessments for the protocol.

 

Our All-127 grant is milestone based, one of the milestones was to present our clinical protocol to the FDA, for comments. The comments took me by surprise. I must hand it to the FDA; they did a great job providing insightful and helpful ideas and advice. It appears that they have learned a lot from the Sanfilippo trials that have gone before me. The San A and B trials have had a rough go at it. Most of them have shutdown entirely or divested, not necessarily because the drug wasn’t working, but because the sponsors didn’t have the bandwidth to give the drug enough time to show change.  I don’t think the sponsors fully appreciated how much time and resources that they would have to commit to their trials. For Sanfilippo it has become abundantly clear that we must put as much time and resources into designing the trials as we put into drug research and development. The FDA was kind enough to give me some ideas on how we might do things better than our predecessors.

 

Based off the FDA’s comments and my mother’s intuition, I pulled out all but one of the clinical outcome assessments that were considered the gold standard for Sanfilippo trials. Breaking the mold is terrifying, I’m ‘Scared all the time but doing it anyway’. This print is hanging in my hairdresser’s salon. It resonated with me. Wish us luck!

 

Thank you for all your support and generous Birthday donations. I want to be able to translate our patient facing documents to as many languages as possible. So that we can enroll more families into our RARE app video assessment. I'm a little shy of my goal. Just saying. https://www.facebook.com/donate/965299684110213/10158889015667215/

 Print by Margaret https://www.margaretstolte.com/
              
My new snapback, Bulbasaur hat, a Bday present from Jonah.


 

Saturday, January 15, 2022

Longing for Loulou

My best birthday ever was Jeremy’s 37th birthday. Jeremy, Jonah, and I traveled to Toulouse France to meet Guilhain, Francine andtheir 2 children, Laura, and Elouan. Our friend Elvis, from Queens, raised in Leone came with us. Elvis helped bridge the language gap and documented our meeting in this video.

This historical trip was 11 years ago this week.  Time flies so fast and I just want to stay in the past. The past being the south of France with our new best friends.

Guilhain met us at the airport grinning from ear to ear, huge hugs, and cheek kisses. Elvis whispered, look out country Frenchmen can be a little handsy. What I wasn’t prepared for was the country Frenchman’s driving style. Holy crap how he flew down the long windy road, sailing up and down the hills. Jeremy, Jonah and I were smashed in the backseat of his little European car. I tried to watch the scenery careen by out the window. It was foggy out and the sun was rising over a chilly winter morning. The road was flanked by acres and acres of fields, I caught glimpses of the shimmery frost on blades of tall grass.  It was literally breathtaking.

We pulled up to their house on the hillside and entered a lovely and lively home. Laura sat at the table watching her mom bustle around the kitchen prepping a breakfast for us. Elouan was dancing in front of the television watching Madagascar singing Let’s Move it Move it. 

Elouan a.k.a. Loulou had Jonah at Bonjour.

Our visit turned out to be our first patient population meeting for Sanfilippo type C and the formation of H.A.N.D.S. 

Belen, Pol’s mom from Barcelona came, she stayed at Guilhain’s sister and brother-in-laws house, who happened to be Spanish. Raquel, Joana’s mom from Lisbon joined as well, she bunked at Laura and Elouans’ grandparent’s house. It was quite the family affair. I loved that the entire family wanted to meet us and take part in helping find and fund a treatment for our children. 

Jeremy and I didn’t realize that we would be wined and dined for a week! Jeremy’s Birthday week no less.  Francine and Guilhain hosted us at the best French restaurants that the south of France had to offer. 

A relation shut down his restaurant to feed all of us, Jeremy had the best French deserts and was sung happy Birthday in 4 different languages (this happened all week long)! A reporter showed up to document the occasion; next day Jonah got to see himself in the paper.

Jonah was absolutely enamored with Elouan, he was 4 years older than Jonah and Jonah was at that age where big boys were like mega super beings to him. 

It is fascinating to watch little kids carry on a conversation in different languages. It really didn’t matter what they were saying, they had the same interests. 

Elouan had an awesome collection of cars that he happily shared with Jonah. The best was Elouan’s kids sized 4-wheeler, it was crazy watching Jonah, still a toddler, hop on that 4-wheeler ready to turn cookies.

 

Joana, Pol, Jonah, Laura and Elouan were all diagnosed within months of each other. We were less than a year into the diagnosis when we all met in person the first time. The diagnosis was still very fresh in our hearts and weighed heavily on our minds. But that week we put our fears aside and rejoiced in finding each other. 

We had already started to raise funds to put towards our gene therapy program at Manchester. Brian Bigger gave us a presentation that week over a skype meeting. I felt so empowered being with all our families, together we would conquer Sanfilippo. I still feel that way.

 


Elouan passed away early morning Friday January 14th a seizure took him while in bed. I don’t know that I ever truly believed that our kids would see a treatment in their lifetime. I hope yet, temper my expectations, truthfully, I don’t let myself think about it.  I think we all just assumed that our kids would make it to their 30’s.  I’m lying I’m terrified that Jonah will die in his sleep and I’ll find him cold in the morning.

 

I just cannot believe that Elouan is gone. I cried all day yesterday. My phone started pinging at 4:30am, I turned it over to look around 6:00am. The shock, that feeling of disbelief, I guess this is how it happens. 

One minute everything is fine the next it’s not. Elouan had his first seizure last year and just a couple since then. We all know seizures can happen to our kids. We still all hope that it doesn’t and then when it does, it takes us by surprise.  

A few months ago, Guilhain messaged me late at night, which meant it was in the middle of the night for him. I asked him if he was having a hard time sleeping. He told me that since Elouan’s first seizure he was too nervous to fall asleep. He stared at Elouan’s room camera watching him sleep instead. Sometimes parents just know. 

France has a relatively large IIIC patient population. There are 4 families with 2 kids each, the 4th family was recently diagnosed and has begun a full front attack on Sanfilippo. Their children are very young, a baby girl Eden and her older brother Abel. It was this family that Guilhain was texting me about that night. He told me that it might be too late for his children, but he was hell bent on helping Eden and Abel.

 


I love you Elouan, thank you for being Jonah’s friend. I’ll never forget the two of you singing and dancing: “LET’S MOVE IT MOVE IT!”

 

This disease is never going to stop unless we stop it. So, let’s move it.

You can donate for a cure in memory of Elouan at the Eden and Abel in French fundraiser  or in English.